Metabolic Dysfunction-Associated Steatohepatitis – Landscape & Forecast – Disease Landscape & Forecast (G7)

The market for metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has great untapped potential owing to the disease’s high prevalence and limited number of approved treatment options (with resmetirom [Rezdiffra] approved only in the United States). Evidence shows that the disease burdens healthcare systems, mainly due to the higher risk of heart disease, liver failure, and liver transplants. Despite guidelines recommending certain medications to manage comorbidities, prescribing is usually limited to specialists treating patients with more-advanced disease. However, with more education about the disease, development of less-invasive diagnostic tools, and availability of approved medical therapies, diagnosis and treatment rates are expected to rise. Over the 2024-2034 forecast period, the MASH market will see the launch of multiple agents from a rich pipeline of emerging therapies, fueling massive market expansion.

Questions answered

• What is the prevalence of MASH, and what is driving its growth?
• How is MASH managed? How has the launch of Madrigal Pharmaceuticals’ resmetirom affected the treatment paradigm in the United States? After its launch, how will the therapy be received in the European markets?
• Which emerging therapy will gain the greatest share in the emerging branded therapy market?
• What do key opinion leaders think about the emerging therapies such as semaglutide, tirzepatide, survodutide, pegozafermin, and efruxifermin?

Geography

United States, EU5, and Japan.

Primary research

Country-specific interviews with thought-leading hepatologists and gastroenterologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology

Diagnosed prevalence of MASH by country; population segmentation by stage of fibrosis.

Forecast

10-year, annualized, drug-level sales and patient share of key MASH therapies through 2034, segmented by brands / generics and epidemiological subpopulations.

Drug treatments

Coverage of key current and late-phase emerging therapies.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.